Skip to content

In the BioHarmony Drug Report Database

Eftrenonacog alfa

Alprolix (eftrenonacog alfa) is a fusion protein pharmaceutical. Eftrenonacog alfa was first approved as Alprolix on 2016-05-12. It has been approved in Europe to treat hemophilia b.
Trade Name Alprolix
Common Name Eftrenonacog alfa
Indication hemophilia b
Drug Class Fc fusion protein
Eftrenonacog alfa
Get full access now